A Pharmacokinetic Study of YN001 in Healthy Participants

NCT07190885 ↗

Phase 1 Recruiting 24 enrolled Beijing Inno Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.

Timeline

Start: 2025-11-18
Primary completion: 2026-02-04
Completion: 2026-02-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YN001	Unknown	20 mg	Intravenous
Subject	YN001	Unknown	40 mg	Intravenous

Indications

No indication recorded.